Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 ResultsGlobeNewsWire • 01/09/22
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine CandidateGlobeNewsWire • 12/16/21
SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap 600PRNewsWire • 11/22/21
Emergent Biosolutions shares plunge by more than 37% after U.S. cancels deal with Covid vaccine makerCNBC • 11/05/21
Emergent Biosolutions shares tumble on news it will lose COVID vaccine production contract with govt'Market Watch • 11/05/21
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Earnings Preview: Emergent Biosolutions (EBS) Q3 Earnings Expected to DeclineZacks Investment Research • 10/28/21
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021GlobeNewsWire • 10/18/21
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLPGlobeNewsWire • 10/15/21
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine CandidateBenzinga • 09/14/21
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-BGlobeNewsWire • 09/14/21